Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

Christian Marth; Rafal Tarnawski; Alexandra Tyulyandina; Sandro Pignata; Lucy Gilbert; Diego Kaen; M Jesús Rubio; Sophia Frentzas; Mario Beiner; Manuel Magallanes-Maciel; Laura Farrelly; Chel Hun Choi; Regina Berger; Christine Lee; Christof Vulsteke; Kosei Hasegawa; Elena Ioanna Braicu; Xiaohua Wu; Jodi McKenzie; John J Lee; Vicky Makker

doi:10.1136/ijgc-2021-003017

Citation Tools

other Versions

You are currently viewing an earlier version of this article (January 10, 2022).
View the most recent version of this article

PDF

Clinical trial

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Marth C, Tarnawski R, Tyulyandina A, et al

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

International Journal of Gynecologic Cancer Published Online First: 19 November 2021. doi: 10.1136/ijgc-2021-003017

Log in using your username and password

Main menu

Log in using your username and password

You are here

other Versions

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password